Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer

NCT00371254 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00371254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00371254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
September 30, 2008
Enrollment
55 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastasis